• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is NovoCure (NVCR) A Bargain On Rising Earnings Estimates?

    Simply Wall St·08/30/2026 03:24:22
    Listen to the news

    Shares of NovoCure (NVCR) have moved higher recently after analysts raised earnings estimates, with short term targets pointing to about 50.9% potential upside and a Zacks Rank #2 reflecting this sentiment.

    NovoCure’s recent momentum has been building, with a 30 day share price return of 20.08% and a year to date share price return of 35.82%. The 1 year total shareholder return of 44.53% contrasts with weaker total shareholder returns over three and five years.

    Compare NovoCure's recent momentum and analyst sentiment with a curated list of 44 high quality undervalued stocks that are also priced below what fundamental metrics suggest.

    NovoCure has a focused cancer treatment business and a share price that has recently moved sharply higher. The next step is to see whether that business strength lines up with what the stock now costs.

    Most Popular Narrative: 31.6% Undervalued

    The most followed narrative on NovoCure pegs fair value at $26.07, compared with the latest close of $17.82. That gap is built on some punchy growth and profitability assumptions.

    In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 33.1x on those 2029 earnings, up from -8.8x today. This future PE is greater than the current PE for the US Medical Equipment industry at 27.4x.

    Read the complete narrative. Read the complete narrative.

    Curious what underpins that higher future profit multiple for NovoCure? The narrative leans on faster earnings growth, improving margins and a step up in scale. The exact mix of those levers is where the story gets interesting.

    Result: Fair Value of $26.07 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, there are still clear pressure points for NovoCure, including ongoing losses and reimbursement uncertainty that could limit how much of this bullish narrative plays out.

    Find out about the key risks to this NovoCure narrative.

    Next Steps

    The mix of optimism and concern around NovoCure is clear, so it makes sense to move quickly and weigh the evidence for yourself. To see both sides set out in one place, review the 3 key rewards and 2 important warning signs.

    Looking for more investment ideas beyond NovoCure?

    If NovoCure has sharpened your focus, you can keep that momentum going by lining up your next ideas now instead of waiting for the market to move without you.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.